Novo Nordisk A/S
Software giant SAP becomes Europe’s most valuable firm amid German stock market boom
A general view of the headquarters of SAP AG, Germany’s largest software company on January 8, 2013 in Walldorf, Germany. Thomas Lohnes | Getty Images News | Getty Images Software-maker SAP became Europe’s most valuable company this week, riding a wave of artificial intelligence enthusiasm and German stock market gains. The company had a market […]
Read More
Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Eli Lilly plans to […]
Read More
Novo Nordisk expands discounted Wegovy to all cash-paying U.S. customers
Jakub Porzycki | Nurphoto | Getty Images Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a discounted price of $499 per month at their local pharmacy. U.S.-listed shares of Novo fell more than 2.5% to $74.92 in premarket trading. Novo has also lost its spot […]
Read More
Novo Nordisk’s next-gen obesity drug CagriSema had investors excited. Now they’re not so sure
Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background. Nurphoto | Nurphoto | Getty Images Novo Nordisk‘s hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from […]
Read More
Zepbound copycats remain online despite FDA ban
This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly‘s weight-loss drug Zepbound and its diabetes drug Mounjaro. Online, it doesn’t look like much has changed. Popular websites like Amble, EllieMD, Willow and Mochi Health are all still advertising versions of tirzepatide, the active ingredient in Zepbound. Some, […]
Read More
Two stocks for investors’ buy lists during this sell-off, according to Tim Seymour
Thursday marked yet another day of the broad market sell-off, and that could provide a buying opportunity for Novo Nordisk and Energy Transfer , according to Tim Seymour of Seymour Asset Management. The firm’s founder and chief investment officer appeared on CNBC’s ” Power Lunch ” on Thursday to share his bullish take on those […]
Read More
European markets higher despite global trade uncertainty
Deutsche Bank names autos as ‘growing risk’ for its portfolio Deutsche Bank flagged autos as a “growing risk” for its portfolio that is being “monitored closely given the challenging economic environment in Europe, Electric Vehicles (EV) transition and competition in China,” Germany’s largest lender said in its annual report out Thursday. Europe’s auto sector now […]
Read More
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma’s obesity drug candidate, as the two firms seek to compete in the burgeoning weight loss drug market. The deal will see the two companies co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as […]
Read More
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. […]
Read More
European markets open lower; Novo Nordisk, Novartis retreat
European markets opened lower on Tuesday as global markets buckle amid anxiety that the U.S. economy will suffer because of President Donald Trump’s trade tariff policies. The pan-European Stoxx 600 index was around 0.2% lower shortly after the opening bell, with the U.K.’s FTSE 100 down 0.2%, while France’s CAC 40 was up 0.3%, and […]
Read More